Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 3 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2Myeloid 1

Conditions

Lymphoma 10Leukemia 10Tumor Lysis Syndrome 7Hyperuricemia 6Leukemia, Myeloid, Acute 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Myelodysplastic Syndromes 3Lymphoma, Non-Hodgkin 3Neoplasms 2Hematologic Neoplasms 2Congenital Abnormalities 2Burkitt Lymphoma 2Blast Crisis 2Waldenstrom Macroglobulinemia 1Sezary Syndrome 1Recurrence 1Primary Myelofibrosis 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Pdgfra-Associated Chronic Eosinophilic Leukemia 1Nutritional and Metabolic Diseases 1Neoplasms, Plasma Cell 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Mycosis Fungoides 1Multiple Myeloma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1

Interventions

venetoclax 27Cyclophosphamide 18Azacitidine 13fludarabine 12ibrutinib 10Busulfan 10fludarabine phosphate 9Rituximab 8Mycophenolic Acid 8Methotrexate 8Cytarabine 8Whole-Body Irradiation 7Peripheral Blood Stem Cell Transplantation 7Clofarabine 7Therapeutics 6Melphalan 6Antilymphocyte Serum 6obinutuzumab 5Tacrolimus 5Surveys and Questionnaires 5Stem Cell Transplantation 5Mesna 5Exercise 5Cyclosporine 5vosaroxin 4trametinib 4thymoglobulin 4ruxolitinib 4ponatinib 4Trimethoprim, Sulfamethoxazole Drug Combination 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasms × rasburicase × Other hematologic neoplasm × Clear all
NCT00230178 2010-01-12

Rasburicase Versus Allopurinol in Tumor Patients at Risk for Hyperuricemia and Tumor Lysis Syndrome

Sanofi

Phase 3 Completed
280 enrolled 10 charts
LymphoidMyeloidOther hematologic neoplasm

Leukemia, Lymphoma, Myelodysplastic Syndromes, Neoplasms, Tumor Lysis Syndrome, Hyperuricemia

NCT00230217 2009-03-30

Study of Rasburicase as Treatment or Prevention of Hyperuricemia Associated With Tumor Lysis Syndrome in Patients With Relapsed or Refractory Lymphoma, Leukemia, or Solid Tumor Malignancy

Sanofi

Phase 4 Completed
94 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Neoplasms, Recurrence, Tumor Lysis Syndrome, Hyperuricemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡